A decade or so ago, the phrase ‘translational research’ began making its rounds through laboratories- it was supposed to take molecular biology results and apply them directly to patients. It brought about things like gene therapy, stem cell therapy, and so forth. You get the idea- valuable research, but not immediately injectable. Valuable and cheap [...]
The Slowing of Drug Discovery
The June 20th issue of Science had an interesting story worth noting (interesting to anyone into molecular pharmacology, anyway), on Drugs, Industry, and Academia. It caught my attention because of some conversations that I’ve been having recently with colleagues and friends in the industry – how is Big Pharma going to maintain itself amid slowing [...]
